Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulthiame dose-guiding phase IIb trial in obstructive sleep apnea
2017-004767-13Phase 2Completed
- Sponsor
- Desitin Arzneimittel
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sultiame in obstructive sleep apnea hypopnea syndrome (OSAHS) (5 arms), sponsored by Desitin Arzneimittel. Primary endpoint: Adverse events including serious adverse events and adverse events of special interest. Started Dec 2017; status: completed.
02
Drugs
sultiame
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2017-004767-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004767-13.